Renal denervation may be effective and safe for treating hypertension in patients with chronic kidney disease, with few major complications encountered (P > 0.05).
Meta-Analysis
Does renal denervation improve blood pressure and renal parameters in patients with chronic kidney disease and hypertension?
Renal denervation appears to be a safe and potentially effective treatment for hypertension in patients with chronic kidney disease, though high-quality RCTs are needed to confirm efficacy.
p-value: p=> 0.05
BACKGROUND: Renal denervation (RDN) is a new treatment for hypertension in patients with chronic kidney disease (CKD), but its efficacy is still debated. This meta-analysis aimed to evaluate the efficacy and safety of RDN for hypertension in patients with CKD. METHODS: PubMed, Web of Science, EMBASE, and Ovid databases were searched for relevant studies published. We performed both fixed- and random-effects meta-analyses of the changes in blood pressure, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR) after RDN. RESULTS: > 0.05), and few major complications were encountered. CONCLUSIONS: The meta-analysis showed that RDN may be effective and safe for treating CKD patients with hypertension. Well-designed randomized controlled trials of RDN are urgently needed to confirm the safety and reproducibility of RDN and to assess its impact on clinical outcomes.
Xia et al. (Fri,) conducted a meta-analysis in hypertension in patients with chronic kidney disease. Renal denervation was evaluated on changes in blood pressure, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR) (p=> 0.05). Renal denervation may be effective and safe for treating hypertension in patients with chronic kidney disease, with few major complications encountered (P > 0.05).